4 ms·
From the Wikipedia page on Curcumin (section Research): In vitro, curcumin exhibits numerous interference properties which may lead to misinterpretation o
by YeGoblynQueenne 9y ago
From the Wikipedia page on Curcumin (section Research):
In vitro, curcumin exhibits numerous interference properties which may lead to
misinterpretation of results.[3][6][20] Although curcumin has been assessed in
numerous laboratory and clinical studies, it has no medical uses established by
well-designed clinical research.[21] According to a 2017 review of over 120
studies, curcumin has not been successful in any clinical trial, leading the
authors to conclude that "curcumin is an unstable, reactive, non-bioavailable
compound and, therefore, a highly improbable lead".[3]
The study claims to have studied a bioavailable forom of curcumin, Theracumin® but it uses a very restricted interpretation of "bioavailability":
The use of adjuvants that block curcumin metabolism, or nanoparticles, liposomes,
phospholipid complexes, and other strategies have improved its bioavailability somewhat,
but only as defined as increased curcumin blood levels8,64–66 with minimum effects on
curcumin availability to the brain.
The study also notes its sample was small:
The relatively small sample size in this study warrants caution in interpreting
our results and limits their generalizability.
It just doesn't sound like their results are going to stand the test of time.
- dumbneurologist 9y agoNone of your criticisms from wikipedia pertain to this publication. The paragraph is essentially making the argument that a randomized, double blind (DB), placebo controlled (PC) clinical trial (RCT) is unlikely to show that curcurmin is effective. yet, the published article is exactly that, and shows a statistically measurable impact on a clinically meaningful endpoint: a direct refutation of the paragraph. the fact the "interference properties" and being an "unstable, reactive, non-bioavailable compound" is subsumed by the study design. claims to have studied a bioavailable form of curcumin This is not really relevant to the claim or conclusions. could it be that the bioavailability matters? maybe. could it be that curcurmin is a trick molecule to study? yes. but come what may, this is direct evidence (not proof) of a cause-effect relationship between this treatment and the outcome. the only thing this effects is the chance that other forms of curcurmin will be comparable (and it might have consequences for regulatory status by the FDA). The study also notes its sample was small This is a very weak criticism when the study is positive (i.e. shows an effect). when the sample size (and statistical power) of the study is small, you need a BIG EFFECT SIZE to be positive. The fact that the trial was positive actually means that it's more likely to be clinically important, because a big effect size means it protects memory in a dramatic way. This is like penicillin: in the pre-antibiotic era, how many cases of pneumonia do you need to treat in order to be satisfied that penicillin is effective? Not bloody many, because the effect size is so dramatic. Likewise for parachutes. few are the therapies that fall into this category, but when you have an inkling that one does following a DB, PC, RCT, you better pay attention. So does it need to be replicated? definitely. does the sponsorship matter? definitely; they could have cheated in some way. until then does it make sense to prescribe this to seniors, or encourage them to increase curcurmin in their diet? quite possibly, given the presumably low rate of adverse effects. Bottom line: this study is not the end-all be-all of curcurmin and memory, but there is legitimate early evidence that the emperor has clothes. edits: mainly spelling, formatting
- closed 9y agoWhen a small sample size produces a big effect, it does not mean you can be more confident in the effect! All things equal, you'd expect confidence intervals / credible regions to be very large. Another way to say this, is that since the measurement error is large, you expect spurious findings that result from something like p-hacking to be large (they have to be to be significant).
- roganp 9y agoThis. This is a relevant podcast featuring John Ioannidis (author of "Why Most Published Research Findings Are False.") http://www.econtalk.org/archives/2018/01/john_ioannidis.html http://www.econtalk.org/archives/2018/01/john_ioannidis.html
- vanderZwan 9y agoWhat annoys me as a someone not trained in statistics is that these discussions are always abstract in-principle arguments about what proper statistics should be like. Meanwhile, we have a real paper with real p-values, why not discuss the validity of that? > SRT Consistent Long-Term Retrieval improved with curcumin (ES = 0.63, p = 0.002) but not with placebo (ES = 0.06, p = 0.8; between-group: ES = 0.68, p = 0.05). Curcumin also improved SRT Total (ES = 0.53, p = 0.002), visual memory (BVMT-R Recall: ES = 0.50, p = 0.01; BVMT-R Delay: ES = 0.51, p = 0.006), and attention (ES = 0.96, p < 0.0001) compared with placebo (ES = 0.28, p = 0.1; between-group: ES = 0.67, p = 0.04). FDDNP binding decreased significantly in the amygdala with curcumin (ES = −0.41, p = 0.04) compared with placebo (ES = 0.08, p = 0.6; between-group: ES = 0.48, p = 0.07). In the hypothalamus, FDDNP binding did not change with curcumin (ES = −0.30, p = 0.2), but increased with placebo (ES = 0.26, p = 0.05; between-group: ES = 0.55, p = 0.02). I can see that there are a lot of p-values around 0.05, but that the supposed improvements have much lower p-values: (ES = 0.63, p = 0.002) SRT Consistent Long-Term Retrieval (ES = 0.53, p = 0.002) SRT Total (ES = 0.50, p = 0.01) BVMT-R Recall (ES = 0.51, p = 0.006) BVMT-R Delay (ES = 0.96, p < 0.0001) attention What does this imply? Is it a good sign, or does it actually make it more fishy? pythonslange's comment[0] seems to suggest the latter, claiming that none of the other pre-registered tests are mentioned, without any explanation why. (eyeing that "attention" one, if this does hold up under scrutiny, could I expect tumeric-based ADD medication somewhere in the future, without all the nasty side-effects of my current amphetamine-based options?) [0] https://news.ycombinator.com/item?id=16229693 https://news.ycombinator.com/item?id=16229693